Table 2 Logistic analysis of the correlation between GREB1L mRNA expression and clinical characteristics in breast cancer
From: GREB1L overexpression is associated with good clinical outcomes in breast cancer
Characteristics | Total (N) | Odds ratio (OR) | p value |
|---|---|---|---|
Age (> 60 vs. <  = 60) | 1083 | 0.997 (0.784–1.267) | 0.978 |
Race (Black or African American &White vs. Asian) | 994 | 1.275 (0.755–2.175) | 0.367 |
Menopause status (Post vs. Pre & Peri) | 972 | 0.835 (0.630–1.106) | 0.208 |
T stage (T2 & T3 & T4 vs. T1) | 1080 | 0.697 (0.529–0.917) | 0.010 |
N stage (N1 & N2 & N3 vs. N0) | 1064 | 1.225 (0.963–1.559) | 0.098 |
M stage (M1 vs. M0) | 922 | 0.815 (0.325–1.987) | 0.652 |
Pathologic stage (Stage III & Stage IV vs. Stage I & Stage II) | 1060 | 0.871 (0.658–1.153) | 0.335 |
Histological type (Infiltrating Lobular Carcinoma vs. Infiltrating Ductal Carcinoma) | 977 | 1.844 (1.348–2.537) |  < 0.001 |
ER status (Positive vs. Negative & Indeterminate) | 1035 | 11.627 (7.811–17.906) |  < 0.001 |
PR status (Positive vs. Negative & Indeterminate) | 1034 | 6.263 (4.669–8.482) |  < 0.001 |
HER2 status (Positive vs. Negative & Indeterminate) | 727 | 0.908 (0.637–1.293) | 0.594 |
PAM50 (Basal vs. Normal & LumA & LumB & Her2) | 1083 | 0.116 (0.074–0.176) |  < 0.001 |
Anatomic neoplasm subgroup (Right vs. Left) | 1083 | 0.786 (0.619–0.998) | 0.048 |
Radiation therapy (Yes vs. No) | 987 | 1.122 (0.872–1.443) | 0.371 |